Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.

ABSTRACT:

Background

Vonoprazan is a novel potassium-competitive acid blocker which may provide clinical benefit in acid-related disorders.

Aim

To verify the non-inferiority of vonoprazan vs. lansoprazole in patients with erosive oesophagitis (EE), and to establish its long-term safety and efficacy as maintenance therapy.

Methods

In this multicentre, randomised, double-blind, parallel-group comparison study, patients with endoscopically confirmed EE (LA Classification Grades A-D) were randomly allocated to receive vonoprazan 20 mg or lansoprazole 30 mg once daily after breakfast. The primary endpoint was the proportion of patients with healed EE confirmed by endoscopy up to week 8. In addition, subjects who achieved healed EE in the comparison study were re-randomised into a lo

SUBMITTER: Ashida K 

PROVIDER: S-EPMC4738414 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature